Chris Martin
Chief Executive Officer, Director
pharmaceutical sciences
adc therapeutics
Netherlands
Biography
Chris Martin is Chief Executive Officer and Director of ADC Therapeutics since June 2015. He played an important role in the formation of ADC Therapeutics in 2011, and has served on its board of directors since its founding. Previously Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to AstraZeneca in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Prior to the acquisition by AstraZeneca MedImmune, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics. He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.
Research Interest
